Dividend compounder review

TARS

Tarsus Pharmaceuticals Inc · NASDAQ · US

Healthcare · Biotechnology

Chart Factor Intelligence Back to Screener
Score31.50/100
Confidence78.00/100
DecisionInsufficient Data
RatingAvoid
Scoring

Quality breakdown

Dividend Reliability 0.0 / 25 Payment history, cuts, growth, and regularity.
Dividend Sustainability 10.0 / 20 Payout, free cash flow, dividend cover, and debt.
Business Quality 11.5 / 25 Scale, cash generation, growth, margins, and returns.
Valuation Discipline 3.0 / 15 Yield, P/E, and price stretch versus long-term trend.
Long-Term Trend 7.0 / 15 Trend line, long return history, and drawdown control.
Metrics

Dividend and business context

Dividend Years0
Dividend Yield0.00%
Payout Ratio0.0%
Dividend Cut 5YNo
Net Income$-66.4M
Free Cash Flow$-22.3M
FCF Covers DividendUnknown
Debt / Equity0.25
P/E-
Revenue Growth 5Y68.3%
Net Margin-9.0%
ROE-14.0%
Price vs Trend-11.0%
3Y Return239.5%
5Y Return110.0%
CurrencyUSD
Warnings

Review flags

No usable dividend history found.
Free cash flow is negative.
Dividend diary

Activity record

TARS dividend review warning Warning · Warning

Free cash flow is negative.